Jason V. Coloma is CEO at Maze Therapeutics, Inc. (MAZE). They have made 1 open-market trade across 1 company since 2026, most recently 2026-09-03.
CIK 0001676170
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MAZE | 27,362 | $753K |
Shares reported on the most recent Form 4, priced at the 2026-09-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MAZE | SELL | 2026-09-02 | 2026-09-04 | $26.24 | $594K | -8.5% | +3.2% | — |
| MAZE | SELL · 10b5-1 | 2026-09-01 | 2026-09-03 | $26.29 | $907K | -7.0% | +3.1% | — |
| MAZE | SELL · 10b5-1 | 2026-08-03 | 2026-08-05 | $26.73 | $922K | -1.2% | -7.3% | — |
| MAZE | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $29.98 | $1.0M | -6.6% | -13.2% | -13.4% |
| MAZE | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $26.04 | $725K | +24.2% | +4.0% | +6.8% |
| MAZE | SELL · 10b5-1 | 2026-06-01 | 2026-06-03 | $26.20 | $174K | -2.8% | +30.1% | +6.5% |
| MAZE | SELL · 10b5-1 | 2026-05-22 | 2026-05-27 | $26.01 | $847K | -8.8% | +10.1% | +17.7% |
| MAZE | SELL · 10b5-1 | 2026-05-15 | 2026-05-18 | $26.00 | $50K | +9.0% | +2.4% | +15.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.